2nd Medical Affairs & Rare Disease
West Coast

Cross-Functional Collaboration in Rare Disease:
Breaking Down Silos to Identify Solutions

Event Overview

The new coronavirus has paralyzed our world, but older diseases remain as dangerous as ever.  Rare disease patient needs have become even more challenging in an age of social distancing and fears of contagion.

To help serve the patients who are under the most risk and are least able to wait for society to reopen, Dynamic Global Events invites you to participate in the 2nd annual Medical Affairs & Rare Disease – West Coast conference – this year held entirely streaming online.  At a time when people are forced to stay apart, this forum helps you unite multi-stakeholder teams across functions, organizations, and therapeutic areas, in order to solve problems and identify rare disease solutions.

About the Chairperson

Image

Dr. Matthew T. Roe has been a faculty member at Duke University School of Medine and the Duke Clinical Research Institute (DCRI) since 1999. As a senior investigator at the DCRI, he has been the principal investigator for numerous phase II-IV cardiovascular clinical trials and is currently a co-principal investigator for the ADAPTABLE trial—the first large-scale pragmatic trials being conducted in the PCORnet network. He has also served in leadership roles for several observational registries focusing upon the treatment and outcomes of patients with cardiovascular disease and has served as the Director of the DCRI Clinical Research Fellowship since 2010.

Featured Speakers

Image

Craig Lipset

Head of Clinical Innovation
Pfizer

Image

Jeff Kingsley

Chief Executive Officer
IACT Health 

Image

Dawn Anderson

Managing Director, Life Sciences Strategy and Operations, R&D Practice
Deloitte

Image

Ross Friedberg

General Counsel & Chief Privacy Officer
Doctor on Demand

Top Reasons to Attend

  1. Maps for adapting rare disease development and outreach to a post-COVID world
  2. Detailed strategies for ensuring patient centricity in rare disease clinical trials
  3. Tools for spotting and avoiding the most urgent mistakes that can strike a rare disease program
  4. Insights for building and learning from cross-disciplinary teams
  5. New visions for the medical affairs must-haves for both small and large pharma

Attendee Profile

This conference is designed for senior leaders and executives in pharmaceutical, biotech, and medical device companies responsible for:

  • Rare Disease
  • Orphan Drugs
  • Gene Therapy
  • Medical Affairs
  • Medical Messaging
  • MSL
  • Clinical Affairs
  • Patient Affairs
  • Patient Outreach
  • Patient Engagement
  • Patient Advocacy
  • Medical Publication Planning
  • eClinical
  • Health Economics & Outcomes Research

LIVE Stream | Day 1

9:00 AM

Login

9:00 AM - 9:15 AM

Conference Opening Remarks

Barbara Wuebbels - Chairman
PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE

9:15 AM - 10:00 AM

Creating Strategic Plans for Cross Functional Collaboration and Growth

Andy Overmyer, Head of Global Business Operations
AKCEA THERAPEUTICS

10:00 AM - 10:45 AM

Medical Affairs Do’s and Don’ts – Transitioning from a Small Biotech to a Large Biopharma Company

Oscar Seguardo, MD, Ph.D - Chief Medical Officer
ASC THERAPEUTICS

10:45 AM - 11:00 AM

Break

11:00 AM - 11:45 AM

A Progressive Approach to Rare Disease Medical Publications

The lack of published literature in rare disease presents an impediment to progressing disease understanding and advancing therapies. Companies developing medical publishing programs need to consider that this is not your everyday medical publications program for a more common disease. As an example, to have a more tangible impact, rare disease publications must be open access and freely available to all stakeholders in rare, including the patient. Breaking down the process we will:

  • Discuss the best methods, timelines, and content requirements for rare disease publications
  • Highlight crucial differences between publishing for rare diseases and more common types
  • Encourage that rare disease clinical trial results are shared with the patient community as a priority and in a legally compliant manner

Dan Donovan - Founder & CEO
RARE LIFE SOLUTIONS

11:45 AM - 12:30 PM

Collaborative Private/Public Partnerships for Real World Evidence Collection and Expanded Access to Rare Disease Therapies

Wendy White - Chairman
GLOBAL GENES and Co-Founder, RAREITI

Natalie Douglas - Vice Chairman
GLOBAL GENES and Co-Founder, RAREITI

12:30 PM - 1:30 PM

Lunch

1:30 PM - 2:15 PM

Collaborating Around Rare Disease

Jon Kaskey - Regional Vice President, Business Partnerships
WITHIN3

2:15 PM - 3:00 PM

PANEL: Rare Disease Clinical Research: Literacy, Diversity, Engagement, Technology and Retention

Joan A. Chambers - Senior Director, Marketing and Outreach
CENTER FOR INFORMATION & STUDY ON CLINICAL RESEARCH PARTICIPATION (CISCRP)

Harsha Rajasimha, MS, Ph.D - Founder and Chairman
INDOUSRARE

3:00 PM - 3:15 PM

Break

3:15 PM - 4:00 PM

Deploy Medical Affairs Expertise for Vital Information Gathering to Improve Trial Patient-Centricity and Success

The patient voice must move to the forefront of clinical trial planning, or else you are at risk of missed endpoints, low enrollment, and wasted time and money.  Dedicated MSL teams can be powerful tools for gathering patient information and, in turn, properly structuring your trials.  With their direct access to the patient voice, they are also vital in educating clinical staff about the disease. 

  • Reorient logistics, consent forms, and follow-ups around the patient voice
  • Rely on medical affairs professionals to verify your assumptions about age spread and disease severity
  • Strengthen advisory board meetings through medical affairs input

Barbara Wuebbels - Chairman
PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE

LIVE Stream | Day 2

9:00 AM

Login

9:00 AM - 9:15 AM

Recap of Day 1 & Day 2 Opening Remarks

Christine von Raesfeld - Founder/CEO
PEOPLE WITH EMPATHY

9:15 AM - 10:00 AM

Improve Commercial and Medical Affairs Teamwork when Advancing Pediatric Rare Disease Therapies

Commercial, medical affairs, and medical communications teams must be closely involved from the earliest stages in order to accurately guide sales. This is especially true for rare disease therapeutics for which doctors might see only one patient per month at the most. The entire clinical and medical affairs management cycles for rare disease will have to significantly change in response to the COVID-19 pandemic.

  • Pinpoint the medical affairs and communication partnerships and messaging most essential in new APDS therapeutics
  • Track the key steps in expanding rare disease therapeutics for a new pediatric indication
  • Adapt your methods and messaging to a post-coronavirus world

Colin Scott - Managing Partner
HIGHLAND AIRS CONSULTING

10:00 AM - 10:45 AM

Investments in Empathy: How Collaborative and Meaningful Relationships can Lead to Viable Solutions in Healthcare

  • Create trust among stakeholders
  • Envision innovative partnerships focused on solutions, not profits
  • Prioritize transparency, accountability, and conflict resolution in partnerships
  • Grasp how small investments can lead to big returns

Christine von Raesfeld - Founder/CEO
PEOPLE WITH EMPATHY

Spandan Chakrabarti - Co-Founder/CFO
PEOPLE WITH EMPATHY

Vij Senthilnathan - Board Member
PEOPLE WITH EMPATHY

Jim Murray - Board Member
PEOPLE WITH EMPATHY

10:45 AM - 11:00 AM

Break

11:00 AM - 11:45 AM

Leverage Medical Claims Data to Improve Patient Outcomes

  • Create trust among stakeholders
  • Envision innovative partnerships focused on solutions, not profits
  • Prioritize transparency, accountability, and conflict resolution in partnerships
  • Grasp how small investments can lead to big returns

Robert Consalvo - Director of Strategic Commercial Engagement
H1 INSIGHTS

11:45 AM - 12:30 PM

Standing at the Crossroads of the Neglected

Sarah Krug - Executive Director
CANCER 101

Catharine Young - Executive Director
SHEPHERD FOUNDATION

12:30 AM - 1:30 PM

Lunch

1:30 PM - 2:15 PM

CASE STUDY PRACTICUM: Best Practices for Breaking Down Silos to Identify Solutions

  • Actionable Implications to Achieve Clinical Development, Product Launch Goals,
    Drug Safety and Favorable Outcomes
  • Building High-performing Multi-stakeholder Teams
  • Leading Internal Project Teams Across Functions, Geographies and Therapeutic
    Areas
  • Collaborating Across Organizations -- Science, Business and Non-profits

Thomas Lester - Former Executive Director Program Management
AUDENTES THERAPEUTICS

Steven G. Rizk, PharmD, JD - former Global Process Owner, Scientific Credibility Standards for Evidence Generation
GENENTECH

FEATURED SPEAKERS

Image

Oscar Segurado

ASC Therapeutics

Chief Medical Officer

Image

Joan A. Chambers

The Center for Information & Study on Clinical Research Participation (CISCRP)

Senior Director, Marketing & Outreach

Image

Michael Forstner

PrimeVigilance

Senior Vice President and Head of Pharmacoepidemiology and Risk Management

Image

Dan Donovan

rareLife solutions

Co-Founder & CEO

Image

Robert Consalvo

H1 INSIGHTS

Director of Strategic Commercial Engagement

Image

Jon Kaskey

WITHIN3

Senior Director of Business Partnerships

Image

Sheila Bose

SB Lifesciences Consulting, Inc

President

Image

Christine Von Raesfeld

PEOPLE WITH EMPATHY

Founder / CEO

Image

Angela Ramirez Holmes

Cal Rare

Founder/President

Image

Tom Lester

Audentes Therapeutics

Former Executive Director Program Management

Image

Steven G. Rizk

Rype Health

Senior Director Medical Strategy

Image

Maureen McArthur Hart

Global Genes

Director, Research

Image

Andy Overmyer

Akcea Therapeutics

Head of Global Business Operations

Image

Wendy White

GLOBAL GENES

Chairman

Co-Founder, RAREITI

Image

Natalie Douglas

GLOBAL GENES

Vice Chairman

Co-Founder, RAREITI

Image

Harsha K. Rajasimha

INDOUSRARE

Founder and Chairman

Founder Chairman, Indo US Organization for Rare Diseases

Image

Sarah Krug

CANCER 101

Executive Director

Image

May Orfali

BIOASIS TECHNOLOGIES

Chief Medical Officer

Image

Colin Scott

HIGHLAND AIRS CONSULTING

Managing Partner

Image

Barbara Wuebbels

PROFESSIONAL PATIENT ADVOCATES IN LIFE SCIENCE

Chairman

Image

Spandan Chakrabarti

PEOPLE WITH EMPATHY

Co-Founder/CFO

Image

Vij Senthilnathan

PEOPLE WITH EMPATHY

Board Member

Image

Jim Murray

PEOPLE WITH EMPATHY

Board Member

CONFERENCE REGISTRATION


LIVE STREAM PRICING

STANDARD

Stream Anytime

$896

Interested in registering groups of 10 or more? Contact us directly for pricing.

EVENT SPONSORS


Scarritt Group - Official Media Partner

OFFICIAL LIVESTREAM PROVIDER

MEDIA PARTNERS


PM360 - Media Partner

PREMIER MEDIA PARTNER


MEDIA PARTNERS

Image

PREMIER MEDIA PARTNER